NeRRe Therapeutics

What NeRRe Therapeutics does

NeRRe Therapeutics is a privately-held clinical-stage biopharmaceutical company founded in 2012 and headquartered in Stevenage, United Kingdom. The company is developing orvepitant, a proprietary neurokinin-1 (NK1) receptor antagonist designed to block substance P signaling in vagal afferent nerves implicated in the cough reflex. Orvepitant is being advanced through Phase 2 clinical trials as a targeted treatment for chronic cough associated with idiopathic pulmonary fibrosis (IPF), an indication with no currently approved targeted therapies. NeRRe Therapeutics operates as a single-asset, single-product biotech with no other compounds in its disclosed pipeline.

The company's business model is pre-revenue and dependent on venture capital financing to fund clinical development. NeRRe has raised approximately $74.6M across three funding rounds (2012, 2017, 2021), with the most recent being a £20M Series B2 in July 2021 led by Columbus Venture Partners, alongside Advent Life Sciences, Forbion, Fountain Healthcare Partners, OrbiMed, and The Future Fund. The company anticipates generating future revenue through direct commercialization or out-licensing of orvepitant to established pharmaceutical partners, with planned distribution through specialty pharmacy networks and hospital formularies targeting pulmonologists and respiratory specialists upon regulatory approval. The broader chronic refractory cough market spans an estimated 12.9 million cases in the US and significant patient populations across the EU4, UK, and Japan, providing substantial addressable market potential beyond the initial IPF indication.

Name

NeRRe Therapeutics

Website

https://nerretherapeutics.com

Company type

Private

Founded year

2012

Operating status

Operating

Headcount range

11–50 employees

Short description

NeRRe Therapeutics is a UK-based clinical-stage biotech developing orvepitant, a neurokinin-1 receptor antagonist currently in Phase 2 trials for chronic cough associated with idiopathic pulmonary fibrosis, an indication with no approved targeted therapies.

Ownership category

akta.pro rank

Product category

Respiratory Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medicinal and Botanical Manufacturing (325411)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF)

akta.pro secondary industry

Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)

Keywords

• Chronic cough therapeutics
• Neurokinin receptor antagonists
• Respiratory drug development
• Pulmonary fibrosis treatments
• Clinical stage biotechnology

Headquarters

HQ city

Stevenage

HQ country

United Kingdom

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations

Revenue model

1. Pharmaceutical product revenue: Pre-revenue clinical stage biopharmaceutical company. Expected to generate revenue through sales of orvepitant upon successful regulatory approval and commercialization for treatment of chronic cough associated with IPF and potentially other chronic cough indications.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

NeRRe Therapeutics is a clinical-stage biotechnology company developing orvepitant, a novel neurokinin-1 (NK1) receptor antagonist, as a targeted treatment for chronic cough associated with idiopathic pulmonary fibrosis (IPF). The drug candidate works by blocking substance P signaling in vagal afferent nerves involved in the cough reflex, and is currently advancing through Phase 2 clinical trials.

Product overview

NeRRe Therapeutics is a single-product biotech company focused on developing orvepitant, a novel neurokinin-1 receptor antagonist, as a targeted treatment for chronic cough associated with idiopathic pulmonary fibrosis (IPF). The company is advancing this drug candidate through Phase 2 clinical trials, funded by a £20 million Series B2 funding round. The company does not appear to offer a platform architecture or multiple products—their portfolio centers exclusively on this one therapeutic candidate.

Differentiator

Problem solved

Functional benefit

Products and services

• Orvepitant

Quantifiable outcome

• Phase 2 clinical trials in progress to establish efficacy for chronic cough treatment in IPF patients

Segments2 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Scale indicators2 records

Recent moves5 records

Expansion highlights4 records

Direct peers

• Bellus Health: Canadian clinical-stage biotech developing P2X3 antagonists (camlipixant) for chronic cough. Direct competitor in the same patient population and indication NeRRe targets with a different mechanism of action.
• Neumentum: Clinical-stage company developing non-opioid therapeutics for chronic cough and pain, directly competing with NeRRe for the chronic refractory cough patient population.
• Cara Therapeutics: Biotech developing neurokinin-1 receptor antagonists (including oral and IV formulations) for pruritus and other indications. Directly comparable as an NK1-focused small-molecule developer.
• Pliant Therapeutics: Biotech developing therapeutics for idiopathic pulmonary fibrosis and other fibrotic diseases, directly overlapping with NeRRe's IPF patient population and chronic cough indication.

Broad incumbents

• Merck & Co. (via Afferent Pharma / gefapixant program): Merck advanced gefapixant, a P2X3 antagonist, through late-stage development and filings for refractory chronic cough. A large pharma incumbent directly competing for the same chronic cough patient population targeted by orvepitant.
• FibroGen: Developed pamrevlumab for IPF, directly relevant as a competitor targeting the same IPF patient population that NeRRe addresses for the chronic cough symptom.
• United Therapeutics: Commercial-stage company marketing Tyvaso (treprostinil) for pulmonary hypertension and PH-ILD, including IPF patients. A relevant incumbent in IPF therapeutics with overlapping patient reach.
• Boehringer Ingelheim (Ofev / nintedanib): Markets nintedanib (Ofev), one of two FDA-approved therapies for IPF. The dominant standard-of-care incumbent whose IPF patient population overlaps NeRRe's targeted cough indication.

Emerging players

• Trevena: Clinical-stage biopharmaceutical company focused on CNS and respiratory indications with novel small-molecule therapies, broadly comparable in stage and therapeutic area focus to NeRRe.
• Galapagos NV: Biotech that advanced ziritaxestat and other IPF candidates through clinical development, providing a comparable clinical-stage IPF competitor with similar development-stage profile to NeRRe.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/nerre-therapeutics-ltd

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds3 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NeRRe Therapeutics